Transform patient outcomes by bringing the cellular biology of depression into its diagnosis and treatment
Our Diagnostic Blood Test:
Commercialization of a patented biomarker-based blood test to assist physician diagnosis and treatment efficacy for each patient diagnosed and in treatment for depression. A variant of this is in development for a prospective predictive screen using a patient's leukocytes to guide treatment options, including drug combinations.
MoodMarkDx® and MoodMarkRx® will be the first evidence-based tests to provide unbiased, biological evidence of depression diagnosis and treatment-response prediction derived from physiological changes specific to clinical depression. U.S. and international patents protect Pax's biomarker assays for antidepressant drug development and Pax's blood tests.
Our Drug Development Services Business:
We are offering pharmaceutical and biotechnology companies the opportunity to work with Pax to analyze antidepressant compounds in early stage discovery and antidepressant clinical trials. In clinical trials, the blood test can streamline recruitment by identifying potential subjects who are and are not biologically depressed, identify responders and non-responders, provide quantitative data, produce greater efficiencies in development, lower costs, and develop better drugs. Preclinical neurobiology and central nervous system (CNS) drug discovery solutions allow the company to work with pharmaceutical companies to identify and validate targets, select new compounds, and reposition or repurpose shelved compounds.
Revenues generated from drug development services are intended to bootstrap the continued development of the blood test assay for the consumer and pharmaceutical markets, and to explore novel pathways for antidepressant development.
Mark M. Rasenick, PhD
President & Chief Scientific Officer
Distinguished professor of physiology and psychiatry, specializing in the biology of mood disorders, and long-time advisor to policymakers on mental health.
Helene J. Shambelan, JD
Chief Executive Officer
Former law professor focused on corporation and securities law, concentrating for over a decade on the areas of health and biotechnology.
Steven D. Targum, MD
Chief Medical Officer
Former professor and chair of psychiatry with three decade expertise in clinical trial methodology and drug development strategy.
Scientific Advisory Board
Mark M. Rasenick, PhD
Paul Billings, MD, PhD
Eric Nestler, MD, PhD
Mark Rapaport, MD
Natalie Rasgon, MD, PhD
Alan F. Schatzberg, MD
Steven Targum, MD
Madhukar Trivedi, MD